© 2005 European Society for Medical Oncology
Original article |
Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)–paclitaxel or docetaxel adjuvant chemotherapy in breast cancer
Hospital of the University of Pennsylvania, Philadelphia, PA, USA
* Correspondence to: Dr J. Schwartz, Women and Infants Hospital, 101 Dudley Street, Providence, RI 02905, USA. Tel: +1-401-274-1122; Email: jschwartz{at}wihri.org
Background: Results of CALGB 9741 demonstrated that administering standard doxorubicin/cyclophosphamide (AC)–paclitaxel therapy for adjuvant therapy of breast cancer in a dose-dense fashion with colony-stimulating factors increases efficacy, decreases severe neutropenia, but may increase the need for blood transfusions. A chart review was performed to evaluate the rates of anemia, neutropenia and skin toxicities with dose-dense and traditional AC–taxane chemotherapy.
Patients and methods: A total of 112 patients received one of four treatments: non-dose-dense AC–paclitaxel (NDD Pac), dose-dense AC–paclitaxel (DD Pac), non dose-dense AC–docetaxel (NDD Doc), or dose-dense AC–docetaxel (DD Doc).
Results: Transfusion rates were not increased in the dose-dense population; however, rates of grade 2–4 anemia (23% versus 0%, P=0.029), as well as erythropoietin use (58% versus 0%, P <0.0001), were significantly increased in the DD Pac group compared with the NDD Pac group. Grade 3 skin toxicities were significantly increased in the DD Doc group compared with the NDD Doc group (70% versus 11%, P <0.0001).
Conclusions: These results demonstrate that dose-dense AC–taxane therapy may increase rates of anemia and the need for erythropoietin, and decrease rates of neutropenia. The utility of DD Doc appears limited by skin toxicities and its use outside of a clinical study should not be recommended.
Key words: anemia, breast cancer, docetaxel, dose-dense, doxorubicin, erythropoietin, hand–foot syndrome, neuropathy, paclitaxel
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P Piedbois, D Serin, F Priou, P Laplaige, S Greget, E Angellier, E Teissier, J-F Berdah, M Fabbro, B Valenza, et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study Ann. Onc., January 1, 2007; 18(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|